ATE168472T1 - Nachweis von prostat-spezifischen antigen in brusttumoren - Google Patents

Nachweis von prostat-spezifischen antigen in brusttumoren

Info

Publication number
ATE168472T1
ATE168472T1 AT94915490T AT94915490T ATE168472T1 AT E168472 T1 ATE168472 T1 AT E168472T1 AT 94915490 T AT94915490 T AT 94915490T AT 94915490 T AT94915490 T AT 94915490T AT E168472 T1 ATE168472 T1 AT E168472T1
Authority
AT
Austria
Prior art keywords
prostate
pct
specific antigen
detection
breast tumors
Prior art date
Application number
AT94915490T
Other languages
English (en)
Inventor
Eleftherios P Diamandis
Original Assignee
Nordion Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordion Int Inc filed Critical Nordion Int Inc
Application granted granted Critical
Publication of ATE168472T1 publication Critical patent/ATE168472T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94915490T 1993-05-14 1994-05-13 Nachweis von prostat-spezifischen antigen in brusttumoren ATE168472T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939309966A GB9309966D0 (en) 1993-05-14 1993-05-14 Detection of prostrate-specific antigen in breast tumors

Publications (1)

Publication Number Publication Date
ATE168472T1 true ATE168472T1 (de) 1998-08-15

Family

ID=10735488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915490T ATE168472T1 (de) 1993-05-14 1994-05-13 Nachweis von prostat-spezifischen antigen in brusttumoren

Country Status (8)

Country Link
US (2) US5688658A (de)
EP (1) EP0698215B1 (de)
JP (1) JPH09500715A (de)
AT (1) ATE168472T1 (de)
CA (1) CA2161778C (de)
DE (1) DE69411733T2 (de)
GB (1) GB9309966D0 (de)
WO (1) WO1994027152A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5723302A (en) * 1993-05-14 1998-03-03 Nordion International Inc. Detection of prostate-specific antigen in breast tumors
GB9309966D0 (en) * 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
WO1996021042A2 (en) * 1995-01-04 1996-07-11 Trustees Of Boston University Primers for the pcr amplification of metastatic sequences
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
AU8259798A (en) 1997-06-20 1999-01-04 George G Klee Method for detection of breast cancer
US6300088B1 (en) * 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
CA2330628A1 (en) * 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US6352834B1 (en) 1998-07-17 2002-03-05 University Of Iowa Research Foundation Prostate cancer assays and related methods
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
JP2004510161A (ja) * 2000-09-25 2004-04-02 アボット・ラボラトリーズ 高分子ポリカチオンを用いることにより、特異的結合アッセイにおける血清または血漿含有アッセイ試料の干渉を減少させるための方法及びキット
WO2002044418A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
PL365704A1 (en) * 2000-11-28 2005-01-10 Wyeth Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
BR0115728A (pt) * 2000-11-28 2003-09-23 Wyeth Corp Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB187283A (en) 1921-06-20 1922-10-20 John Frederick Simmance Improvements relating to pressure gauges and the like
FI76119C (fi) * 1986-02-27 1988-09-09 Orion Yhtymae Oy Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
GB9309966D0 (en) * 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors

Also Published As

Publication number Publication date
US6261766B1 (en) 2001-07-17
CA2161778C (en) 2002-06-25
US5688658A (en) 1997-11-18
CA2161778A1 (en) 1994-11-24
GB9309966D0 (en) 1993-06-30
DE69411733T2 (de) 1999-04-01
EP0698215A1 (de) 1996-02-28
EP0698215B1 (de) 1998-07-15
AU674078B2 (en) 1996-12-05
WO1994027152A1 (en) 1994-11-24
AU6718694A (en) 1994-12-12
DE69411733D1 (de) 1998-08-20
JPH09500715A (ja) 1997-01-21

Similar Documents

Publication Publication Date Title
ATE168472T1 (de) Nachweis von prostat-spezifischen antigen in brusttumoren
Schwartz Cutaneous metastatic disease
DE69519796D1 (de) PTPalpha-Bestimmung in der Tumordiagnose und -Prognose
DE69631896D1 (de) Murines modell für menschliche karzinome
ES2080717T3 (es) Hibridomas productores de anticuerpos monoclonales para nuevos epitopos de mucina.
JPS6447392A (en) Monoclonal antibody
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
BR0208603A (pt) Marcadores de tumor para carcinoma de células renais
ATE299180T1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
SE8700805L (sv) Monoklonala antikroppar och antigen for icke-smacelligt humanlungkarcinom och vissa andra humankarcinom
HUT77438A (hu) Kalkonok és kalkon-észterek alkalmazása a méh, petefészek és emlő daganatai elleni gyógyszerkészítmények előállítására
Adrover et al. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
Von Kleist et al. Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
DE69714591D1 (de) Prostatakrebs- spezifischer antikörper für immundetektion und immuntherapie
EP0641385A4 (de) Entwicklung von dns-sonden und immunologischen reagenzien von menschlichen tumor-assoziierten antigenen.
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
ATE61734T1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
Shah et al. Prostatic carcinoma metastatic to bone: sensitivity and specificity of prostate‐specific antigen and prostatic acid phosphatase in decalcified material
EP1023459A4 (de) Bestimmung der vorhandenen mengen an cyclin-abhängigem kinase-inhibitor p27 als prognostischem faktor bei krebspatienten
Dobrowolski et al. Prognostic value of beta human chorionic gonadotrophin in blood serum of patients with urinary bladder tumous
Efremidis et al. Anti-common acute lymphoblastic leukemia antibody (CALLA)(J5) reactivity by small cell lung cancer (SCLC) cells
ATE425991T1 (de) Bestimmung von bone-sialoprotein in kírperflussigkeiten fur onkologische fragestellungen
Shima et al. Immunohistochemical detection of matrix metalloproteinase-2/type IV collagenase in esophageal carcinoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties